Sector News

Pfizer promotes prescription drug help and the power of science in new TV ads aimed at COVID-19 concerns

April 22, 2020
Life sciences

In new TV ads, Pfizer is tackling two key concerns brought on by the COVID-19 pandemic. The first commercial addresses how people struggling with unemployment or insurance loss can get help paying for prescription medicines, while the second tackles the uncertainty and anxiety many people feel right now, assuring viewers that “science will win.”

The prescription TV ad, which debuted Tuesday, details the Pfizer prescription medicine assistance program along with income guidelines and the kinds of help patients can get to pay for Pfizer medicines. It ends with a directive to viewers to learn more at the website for Pfizer RxPathways.

The second commercial, launched last week, features working lab video along with real photos of Pfizer scientists with a voice-over that talks about the power of science.

The narrator begins by saying: “At a time when things are uncertain, we turn to the most certain thing there is—science. Science can overcome diseases, create cures and yes, beat pandemics. It has before; it will again.”

While the video used in the ad is stock footage Pfizer had on hand—social distancing prevents shooting a new commercial—the photos of Pfizer scientists who appear at the end of the ad holding signs that read “Science Will Win” are real employees that work on vaccines and antiviral treatments.

Pfizer asked its scientists and researchers in its Groton, Connecticut, and Pearl River, New York, labs to send photos in real time from their work to put in the ad, a Pfizer spokesperson said in an email. The ads end with a thank-you note to all the scientists working in the company’s labs and in labs around the world to end the health crisis.

“Our goal is that the message of hope (‘Science Will Win’) and help (Pfizer RxPathways) will be meaningful in the current environment,” she said.

The ads will run on TV and on social media on YouTube, Facebook, Twitter and LinkedIn.

Along with the prescription help and messages of hope—Pfizer created a “thank you” ad to the men and women on the front lines and a social media explainer series featuring its experts—Pfizer previously announced that it would donate $40 million for both emergency relief funds and grants for the needs of healthcare workers involved the COVID-19 response.

Pfizer also joined with Eli Lilly and Merck to create a joint initiative that deploys employees with medical and lab expertise to volunteer with local healthcare systems.

By: Beth Snyder Bulik

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”